Pantheon Vision is developing bioengineered corneal implants to treat corneal blindness, a condition affecting over 12.7 million people worldwide due to the lack of available donor tissue. Their technology aims to improve graft acceptance and vision restoration, making treatment more accessible in both emerging and developed markets.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Corneal blindness affects millions worldwide, often due to infection, disease, or trauma, leading to opacity of the cornea. A significant barrier to treatment is the limited availability of donor corneal tissue and trained surgeons, particularly in low-to-middle-income countries, leaving many without access to sight-restoring surgery. Current corneal transplant procedures also require improvements in graft acceptance, vision restoration, and longevity.
Solution
Pantheon Vision is developing bioengineered corneal implants designed to address corneal blindness and reduce reliance on donor tissue. Their bioengineered solutions aim to improve graft acceptance, vision restoration, and overall accessibility of treatment for patients in both emerging and developed markets. By creating measurably safe, effective, and scalable products, Pantheon Vision seeks to provide revolutionary solutions that can cure corneal blindness and enable patients to regain sight. The company's technology aims to overcome the limitations of traditional corneal transplants, offering a more readily available and potentially more effective treatment option.
Target Audience
The primary target audience includes individuals suffering from corneal blindness treatable by corneal transplant, as well as ophthalmologists and surgeons seeking alternative solutions to donor tissue transplantation.
Features
- Bioengineered corneal implants designed to reduce the need for donor tissue.
- Focus on improving graft acceptance rates compared to traditional transplants.
- Development of solutions accessible and scalable for both emerging and developed markets.
- Products designed to be measurably safe and effective.